Diametric Capital, LP Arcus Biosciences, Inc. Transaction History

Diametric Capital, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$17.14 - $25.47 $190,631 - $283,277	-11,122 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$13.97 - $36.56 $35,497 - $92,898	-2,541 Reduced 18.6%	11,122 $275,000
Q1 2020 May 15, 2020	BUY	$8.78 - $19.28 $119,961 - $263,422	13,663 New	13,663 $190,000

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Diametric Capital, LP with notifications on news.